Home > Healthcare & Medical Devices > Anti-inflammatory Drugs Market

Anti-inflammatory Drugs Market - By Drug Class (Anti-inflammatory Biologics, Corticosteroids), Treatment (Arthritis, Multiple Sclerosis) Route of Administration (Oral, Topical), Sales Channel (Prescription, Over-the-Counter) & Forecast 2023 - 2032

  • Report ID: GMI5976
  • Published Date: Jun 2023
  • Report Format: PDF

Anti-inflammatory Drugs Industry Analysis

Anti-Inflammatory Drugs Market size accounted for USD 104 billion in 2022 and is estimated to grow at 8.4% to reach USD 233.6 billion by 2032 due to increasing prevalence of inflammatory diseases coupled with growing geriatric population.

Anti-Inflammatory Drugs Market

To get more details on this report: Request Free Sample PDF

For instance, according to the World Health Organisation (WHO) report, around 14 million people had rheumatoid arthritis globally in 2021. Similarly. in 2020, according to Gastroenterology Journal, the prevalence of inflammatory bowel disease among elderly individuals appears to be rising by 5.2% annually.

Anti-inflammatory drugs, also known as anti-inflammatories or anti-inflammatory agents, are a class of medications that help reduce inflammation in the body. Anti-inflammatory drugs work by inhibiting, reducing the production and activity of inflammatory mediators such as prostaglandins, cytokines, and leukotrienes. These drugs provide relief from symptoms and help manage inflammatory conditions such as arthritis, inflammatory bowel disease, and other chronic diseases. While these drugs can be effective, it is important to use them under the guidance of a healthcare professional due to potential side effects.

COVID-19 Impact

The COVID-19 pandemic impacted slightly negative on the anti-inflammatory drugs market gains. During the initial phase of the COVID-19 pandemic, various anti-inflammatory drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), were used to manage fever, pain and inflammation associated with COVID-19 symptoms. However, concerns were raised regarding the potential negative effects of NSAIDs on COVID-19 outcomes. These concerns stemmed from the fact that NSAIDs may potentially worsen the immune response and increase the risk of complications.

For instance, the French Health Minister reported that, NSAIDs may be detrimental to patients with COVID-19 due to upregulation of angiotensin-converting enzyme (ACE) 2 expression, which, in turn, may facilitate viral entry into host cells and enhance pathogenicity of the viral load. This concern was also reported in the British Medical Journal, and despite a lack of evidence to confirm such risk, there was a significant reduction in NSAID use at a time when they could have benefitted those infected with COVID-19.

Anti-inflammatory Drugs Market Trends

Increasing prevalence of autoimmune disease and respiratory conditions have significantly created the demand for anti-inflammatory drugs. Autoimmune disease such as rheumatoid arthritis, lupus, and multiple sclerosis are on the rise globally. Various factors such as genetic predisposition, exposure to certain chemicals, hormonal imbalances, smoking, sedentary lifestyle significantly contributes to the autoimmune disease and respiratory conditions.

Therefore, adoption of anti-inflammatory drugs will help suppress the excessive immune response, reduce inflammation and alleviate symptoms. Similarly in respiratory conditions such as asthma and COPD, anti-inflammatory drugs help decrease airway inflammation, bronchoconstriction and mucus production, resulting in improved lung function and symptom control.

Anti-inflammatory Drugs Market Restraint

Side effects associated with the use of anti-inflammatory drugs may significantly impede the market expansion. Major side effects associated with the use of anti-inflammatory medications include gastrointestinal issues such as stomach ulcers, indigestion and gastrointestinal bleeding. Similarly, nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids can also increase the risk of cardiovascular events such as heart attacks and stroke and weight gain, mood change, increase in blood pressure among others respectively.

Anti-inflammatory Drug Class Segmentation

Anti-Inflammatory Drugs Market Size, By Drug Class, 2021 - 2032 (USD Billion)

To get more details on this report: Request Free Sample PDF

By drug class, the anti-inflammatory drugs market is classified into anti-inflammatory biologics, nonsteroidal anti-inflammatory drugs (NSAIDS), corticosteroids and other drug class. Anti-inflammatory biologics segment accounted for 43.7% of the market share in 2022. Anti-inflammatory biologics target specific inflammatory pathways and aids in effectively reducing the inflammation and provide significant relief from symptoms such as pain, swelling, and joint stiffness. They are beneficial in autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease as compared to traditional treatments.

Anti-inflammatory Drugs Treatment Segmentation

Anti-Inflammatory Drugs Market Revenue Share, By Treatment, (2022)

To get more details on this report: Request Free Sample PDF

Based on treatment, the anti-inflammatory drugs market is segmented into arthritis, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), multiple sclerosis and other treatments. The arthritis segment is expected to register over USD 70.5 billion by 2032. Anti-inflammatory drugs help reduce inflammation, relieve pain and improve joint function caused due to arthritis. These drugs provide symptomatic relief and slow down the disease progression by effectively managing arthritis symptoms that allows patients to perform daily activities with greater ease and functionality.

Anti-inflammatory Drugs Route of Administration Segmentation

By route of administration, the anti-inflammatory drugs market is segmented into oral, breast cancer, topical, injection and intranasal. The oral segment is expected to grow at 9.2% by 2032. Oral route of administration includes medication in the form of tablets, capsules and liquids. This route of administration is convenient, easily accessible and can be self-administered at home. Also, the oral form of anti-inflammatory drugs are composed in appropriate proportion that enables the individual to intake the correct proportion of dosage. Furthermore, oral anti-inflammatory drugs have a well-established formulation and manufacturing process, contributing to their widespread availability and affordability.

Anti-inflammatory Drugs Sales Channel Segmentation

The sales channel segment of anti-inflammatory drugs market is divided into prescription and over the counter (OTC) drugs. Prescription segment accounted for USD 54 billion market revenue in 2022. The prescription-based anti-inflammatory drugs are appropriately prescribed, monitored and used under medical supervision. This helps to optimize patient safety and ensures that the medications are used effectively for the intended purposes in appropriate dosage level. Additionally, the prescription sales model provides opportunities for pharmaceutical companies to collaborate with healthcare providers and enables strong establishment with healthcare institutions and pharmacies.

Anti-inflammatory Drugs Regional Analysis  

U.S. Anti-Inflammatory Drugs Market Size, 2020 – 2032 (USD Billion)

North America anti-inflammatory drugs market accounted for over 38.9% market share in 2022. The increasing prevalence of inflammatory diseases such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), psoriasis among others is expected to boost the industry development. Also, growing geriatric population, sedentary lifestyles, and increasing awareness of disease management is expected to further accelerate the demand for anti-inflammatory drugs in the North America region. The advanced healthcare infrastructure, presence of key players and strong R&D facilities have contributed to the significant adoption and commercial success of anti-inflammatory drugs.

Anti-inflammatory Drugs Industry Leaders

Major market players operating in the anti-inflammatory drugs market include AbbVie Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc among others.

Anti-inflammatory Drugs Industry News:

  • In May 2023, AbbVie Inc received U.S. Food and Drug Administration (FDA) approval for RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active Crohn's disease. This product approval is expected to help the company to enhance its product offerings in anti-inflammatory drugs and drive revenue progression.
  • In March 2022, Pfizer Inc acquired Arena Pharmaceuticals. This acquisition enables the company to develop and enhance its product portfolio in gastroenterology, dermatology, and cardiology. This strategic acquisition helped the company to complements its capabilities and expertise in inflammation and immunology division.

The anti-inflammatory drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Drug Class

  • Anti-inflammatory biologics
  • Nonsteroidal anti-inflammatory drugs (NSAIDS)
  • Corticosteroids
  • Other drug class


  • Arthritis
  • Inflammatory bowel disease (IBD)
  • Chronic obstructive pulmonary disease (COPD)
  • Multiple sclerosis
  • Other treatments

Route of Administration

  • Oral
  • Topical
  • Injection
  • Intranasal

Sales Channel

  • Prescription
  • Over the Counter (OTC)

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Anti-inflammatory drugs industry share was USD 104 billion in 2022 and is estimated to record 8.4% CAGR by 2032, attributed to the high prevalence of inflammatory diseases along with the growing geriatric population worldwide.

The oral segment is expected to grow at 9.2% CAGR by 2032, owing to their rising demand for convenience and ease of accessibility.

North America held over 38.9% of the market revenue share in 2022 driven by the advanced healthcare infrastructure with strong R&D facilities in the region.

Some of the prominent market players include AbbVie Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc among others.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 13
  • Tables & Figures: 274
  • Countries covered: 20
  • Pages: 180
Inquiry Before Buying

Budget constraints? Get in touch with us for special pricing

Request Discount